comparemela.com
Home
Live Updates
Transgene to Present Updated Positive Preliminary Data from the Phase I Clinical Trials with TG4050 (myvac platform) at ASCO 2022 : comparemela.com
Transgene to Present Updated Positive Preliminary Data from the Phase I Clinical Trials with TG4050 (myvac platform) at ASCO 2022
Regulatory News: Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announces that an abstract reporting preliminary
Related Keywords
Ankara ,
Turkey ,
United States ,
Paris ,
France General ,
France ,
United Kingdom ,
Chicago ,
Illinois ,
American ,
Lucie Larguier ,
Jean Pierre Delord ,
Sylvie Berrebi ,
Alexandra Martinez ,
Christian Ottensmeier ,
Christophe Le Tourneau ,
Transgene Euronext ,
Le Tourneau ,
Yujie Zhao ,
C Le Tourneau ,
Institut Curie ,
Head Of The Department Drug Development ,
Clatterbridge Cancer Centre ,
American Society Of Clinical Oncology ,
Twitter ,
University Of Liverpool ,
Astrazeneca ,
Corporate Communications ,
Head Of Surgical Department ,
Regulatory News ,
Euronext Paris ,
American Society ,
Clinical Oncology ,
Consultant Medical Oncologist ,
Drug Development ,
Matthew Block ,
Consultant Medical Oncology ,
Consultant Immunology ,
Associate Professor ,
Mayo Clinic ,
Associate Head ,
Surgical Department ,
Vaccinia Ankara ,
Artificial Intelligence ,
Risk Factors ,
Universal Registration Document ,
Transgene ,
Present ,
Pdated ,
Positive ,
Reliminary ,
Data ,
Rom ,
Hase ,
Linical ,
Trials ,
G4050 ,
Myvac ,
Platform ,
Disco ,
022 ,
comparemela.com © 2020. All Rights Reserved.